Septerna, Inc.
SEPNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeSepterna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and. With a market capitalization of $1.89B, it sits in small-cap territory. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease.
Market Cap
$1.89B
Beta
—
P/E (TTM)
—
P/E (Fwd)
-20.82
EPS (TTM)
$-0.54
EPS (Fwd)
$-1.94
ROE
-6.3%
ROA
-7.1%
Cash
$372.3M
Total Debt
$22.5M
Free CF
$29.5M
52W Change
86.5%
Annual Financials
Cash vs Debt
Where SEPN stands vs its 150-day and 200-day moving averages
As of the October 6, 2026 close, SEPN finished 17.39% above its 150-day moving average ($32.26) and 22.40% above its 200-day moving average ($30.94). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SEPN overbought or oversold?
At the October 6, 2026 close, SEPN's RSI(14) was 45.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $372.3M in cash comfortably exceeding the $22.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $29.5M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -6.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. No single metric tells the full story. Reviewing SEPN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.